Ronald M. Bukowski

Ronald M. Bukowski's AcademicInfluence.com Rankings

Ronald M. Bukowski

Philosophy

#5770

World Rank

#8665

Historical Rank

Logic

#2984

World Rank

#4074

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ronald M. Bukowski's Degrees

Doctorate Medicine Harvard University
PhD Biomedical Sciences Stanford University

Why Is Ronald M. Bukowski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronald M. Bukowski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sorafenib in advanced clear-cell renal-cell carcinoma. (2007) (4691)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (2007) (4385)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) (1682)
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. (2009) (1081)
Sunitinib in patients with metastatic renal cell carcinoma. (2006) (965)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009) (832)
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. (1997) (697)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (479)
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. (2009) (462)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. (2007) (433)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (2004) (399)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. (2008) (395)
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. (2013) (394)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. (2007) (378)
The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial (1990) (363)
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) (2005) (359)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. (2007) (315)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. (1998) (305)
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors (2009) (276)
Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients With Renal Cell Carcinoma or Melanoma (2002) (272)
Natural history and therapy of metastatic renal cell carcinoma (1997) (256)
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. (1977) (248)
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2007) (225)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. (1998) (215)
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. (1999) (210)
Estrogen receptor mutations in tamoxifen-resistant breast cancer. (1994) (201)
Sunitinib efficacy against advanced renal cell carcinoma. (2007) (201)
Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. (1993) (199)
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (2008) (195)
Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) (2008) (187)
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. (2003) (184)
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. (1996) (183)
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. (1993) (177)
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. (2009) (175)
Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? (2005) (169)
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (2010) (168)
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) (2005) (163)
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma (2015) (160)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. (2008) (159)
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. (1999) (158)
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. (2003) (150)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. (2008) (145)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis (2007) (144)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. (2008) (144)
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial (2008) (138)
Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results (2007) (137)
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) (2006) (135)
Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. (1976) (133)
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma (2013) (130)
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. (1988) (127)
Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) (2005) (124)
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. (2002) (122)
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. (1999) (122)
Treating cancer with PEG Intron (2002) (119)
The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. (1994) (115)
Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma (2007) (114)
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. (2001) (110)
Inhibition of NF-κB Activity in Human T Lymphocytes Induces Caspase-Dependent Apoptosis Without Detectable Activation of Caspase-1 and -3 (1999) (109)
Targeted therapy for metastatic renal cell carcinoma. (2006) (109)
Cytokine therapy for metastatic renal cell carcinoma. (2001) (109)
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. (1991) (106)
Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. (1992) (106)
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor‐infiltrating lymphocytes (1995) (105)
Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid (2004) (104)
Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. (1990) (102)
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. (1993) (100)
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). (2006) (99)
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. (2005) (98)
Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. (1990) (96)
Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. (1999) (95)
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma (2005) (95)
Successful combination chemotherapy for metastatic parathyroid carcinoma. (1984) (95)
Therapy of thrombotic thrombocytopenic purpura: an overview. (1981) (94)
Effects of Sorafenib on Symptoms and Quality of Life: Results From a Large Randomized Placebo-Controlled Study in Renal Cancer (2007) (93)
Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors (2007) (92)
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. (1997) (90)
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. (1994) (90)
The management of recurrent ovarian cancer. (2007) (88)
A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A southwest oncology group study (1987) (88)
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid (1994) (88)
Therapy and outcome of small cell carcinoma of the kidney (2003) (87)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (87)
The role of inflammation in kidney cancer. (2014) (87)
Alterations in NFκB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma (1999) (87)
Development and validation of a scale to measure disease-related symptoms of kidney cancer. (2007) (86)
GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. (2006) (85)
T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. (1995) (83)
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). (2006) (83)
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer (2001) (82)
Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). (2006) (82)
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. (1998) (81)
Phase 1 trial of Anvirzel™ in patients with refractory solid tumors (2006) (80)
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. (1998) (80)
Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. (2003) (80)
Caspase-dependent and -independent death pathways in cancer therapy (2000) (80)
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. (1994) (79)
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients (2002) (78)
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. (1987) (78)
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses (2004) (78)
A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab (2008) (77)
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. (1999) (76)
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. (2004) (74)
Prognostic Factors in Patients with Advanced Renal Cell Carcinoma (2004) (73)
Patients With Renal Cell Carcinoma or Melanoma (2002) (72)
Randomized trial of 5‐fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study (1983) (72)
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (2014) (71)
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. (2003) (70)
Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis (2007) (68)
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (2010) (67)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (2016) (66)
A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (2009) (66)
Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. (2004) (65)
Myeloid-derived suppressor cells: A novel therapeutic target (2009) (63)
Interleukin-2 in Cancer Therapy (2000) (62)
Phase I Clinical Trial of Interleukin 2 and α-Interferon: Toxicity and Immunologic Effects (1989) (62)
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. (1993) (61)
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. (2006) (61)
Impaired Activation of NFκB in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, IκB (1998) (61)
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. (1990) (60)
Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach (2007) (60)
Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). (2006) (60)
Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity* (2003) (60)
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. (2007) (59)
Treatment of patients with metastatic renal cell cancer (2006) (59)
Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra. (1995) (58)
Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). (2006) (57)
Alternating combination chemotherapy in patients with extragonadal germ cell tumors a southwest oncology group study (1993) (57)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy (2007) (56)
A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) (2007) (55)
Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. (1991) (55)
Sequential use of targeted agents in the treatment of renal cell carcinoma. (2011) (54)
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma (2005) (54)
Hepatic artery infusion of 5‐fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma (1984) (54)
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. (2006) (54)
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (2006) (54)
Degradation of NF-κB in T Cells by Gangliosides Expressed on Renal Cell Carcinomas1 (2004) (54)
Gastric epithelial atypia associated with hepatic arterial infusion chemotherapy. Its distinction from early gastric carcinoma (1985) (53)
Magnetic resonance with marked T2-weighted images: improved demonstration of brain lesions, tumor, and edema. (1985) (53)
Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. (2001) (52)
Mechanism of apoptosis induced by zinc deficiency in peripheral blood T lymphocytes (2001) (52)
Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. (2002) (51)
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors (1997) (50)
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. (2000) (49)
Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds (2005) (49)
Efficacy of multimodality therapy in advanced renal cell carcinoma. (1998) (48)
Prognostic factors for survival in metastatic renal cell carcinoma (2009) (47)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC) (2007) (47)
T-cell adoptive immunotherapy of metastatic renal cell carcinoma. (1999) (46)
Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. (2007) (46)
Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma (1999) (45)
A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors (2007) (45)
Roles of NF-κB and 26 S Proteasome in Apoptotic Cell Death Induced by Topoisomerase I and II Poisons in Human Nonsmall Cell Lung Carcinoma* (2001) (45)
Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival (2006) (44)
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. (2009) (44)
Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers (2007) (44)
The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. (1987) (44)
Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program (2010) (43)
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma (2005) (43)
Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. (1994) (43)
Simultaneous treatment with cisplatin and radiation therapy for advanced solid tumors: a pilot study. (1981) (43)
PROSTACYCLIN THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA (1980) (42)
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. (1992) (42)
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. (2008) (42)
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A southwest oncology group study (1993) (42)
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. (1992) (42)
Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. (2000) (42)
Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival (2007) (41)
Til from renal‐cell carcinoma: Restimulation with tumor influences proliferation and cytolytic activity (1990) (41)
Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. (1999) (41)
Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. (2006) (40)
Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas (2000) (40)
Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. (1999) (40)
Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma (2008) (39)
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. (2008) (39)
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma (2008) (39)
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. (1997) (39)
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. (2006) (39)
Casein kinase I δ/ɛ phosphorylates topoisomerase IIα at serine-1106 and modulates DNA cleavage activity (2008) (38)
Immunotherapy of disseminated renal cell carcinoma with transfer factor. (1977) (38)
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. (1996) (38)
Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin (2005) (37)
Clinical practice guidelines: renal cell carcinoma. (1997) (37)
Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways1 (2008) (37)
Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. (1979) (36)
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. (1994) (35)
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. (1994) (35)
Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma (2012) (35)
Retroperitoneal malignancies several years after initial treatment of germ cell cancer of the testis (1984) (34)
A Phase I–II trial of polyethylene glycol‐conjugated L‐asparaginase in patients with multiple myeloma (2003) (34)
Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. (1990) (34)
Intra-arterial chemotherapy as an adjuvant to surgery in transitional cell carcinoma of the bladder. (1986) (33)
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. (2007) (33)
Temsirolimus: a safety and efficacy review (2012) (33)
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. (2008) (33)
Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction. (2004) (32)
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. (2009) (32)
Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors (1993) (32)
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. (1980) (32)
The promise of targeted therapy: cancer drugs become more specific. (2004) (32)
Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma (2010) (32)
Amifostine (Ethyol): dosing, administration and patient management guidelines. (1996) (31)
Pseudo-gamma heavy chain (IgG4 lambda) deposition disease. (1992) (31)
The need for cytoprotection. (1996) (31)
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma (2003) (31)
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. (1995) (31)
Nephron sparing surgery in patients with metastatic renal cell carcinoma. (1996) (31)
Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest (2006) (31)
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. (2007) (31)
Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). (2006) (31)
Renal cell carcinoma : molecular biology, immunology, and clinical management (2000) (30)
Combination chemotherapy of metastatic thyroid cancer. Phase II study. (1983) (30)
Telomerase activity in Stage II colorectal carcinoma (2002) (30)
Phase II trial of 5‐fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM‐S) in pancreatic carcinoma (1982) (29)
T cell lymphoma occurring in Sjögren's syndrome. (1984) (29)
Phase II trial of subcutaneously administered granulocyte‐macrophage colony‐stimulating factor in patients with metastatic renal cell carcinoma (1996) (29)
RANDOMISED PHASE III TRIAL OF THE MULTIKINASE INHIBITOR SORAFENIB (BAY 43-9006) IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) (2006) (29)
Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. (2006) (28)
Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. (1997) (28)
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET (2010) (28)
Innovations and Challenges in Renal Cancer (2004) (28)
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects. (1990) (28)
Immunotherapy of Renal Cell Carcinoma (1999) (27)
Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC) (2007) (27)
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1 (2008) (27)
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors (2007) (26)
Prognostic factors affecting remission, remission duration, and survival in adult acute nonlymphocytic leukemia (1979) (26)
Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. (1997) (26)
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors (2010) (26)
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. (2015) (26)
Lymphocyte Subpopulations in Hodgkin’s Disease (1976) (25)
New and modified interferon alfas: Preclinical and clinical data (2003) (25)
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). (2010) (25)
Phase I study of WR-2721 and carboplatin. (1993) (25)
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. (2000) (25)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC) (2007) (25)
Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. (2006) (25)
Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008) (24)
Molecular Mechanisms of Immune Dysfunction in Renal Cell Carcinoma (2000) (24)
Interleukin 7 enhances the proliferation and effector function of tumor‐infiltrating lymphocytes from renal‐cell carcinoma (2009) (24)
Thrombotic thrombocytopenic purpura: a review. (1982) (24)
Randomized controlled trial of transfer factor in stage II malignant melanoma (1983) (24)
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. (1982) (24)
Acute nonlymphocytic leukemia in patients receiving chemotherapy for nonmalignant diseases. (1980) (24)
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. (1999) (23)
Adenocarcinoma of the Esophagus and Gastroesophageal Junction Clinical and Pathologic Assessment of Response to Induction Chemotherapy (1994) (23)
TNF-α Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction1 (2007) (23)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM) (2007) (23)
The T cell death knell: immune-mediated tumor death in renal cell carcinoma. (2001) (23)
Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial (2011) (23)
Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: results and followup. (1989) (23)
Biomarkers in clear cell renal cell carcinoma (2007) (22)
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects. (1993) (22)
HIV infection among Brazilian transvestites in a prison population. (1996) (22)
Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. (1999) (22)
Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. (2004) (22)
A critical review of immunotherapy of disseminated renal adenocarcinoma (1982) (22)
Induction by interleukin-2 of oligoclonal expansion of cultured tumor-infiltrating lymphocytes. (1990) (21)
Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components. (1996) (21)
A phase I trial of 5‐fluorouracil, folinic acid, and alpha‐2a‐interferon in patients with metastatic colorectal carcinoma (1992) (20)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment (2007) (20)
Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors (2007) (20)
CURRENT CLINICAL ONCOLOGY (2003) (20)
Evolving role of pegylated interferons in metastatic renal cell carcinoma (2003) (20)
A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. (2006) (20)
Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. (2001) (20)
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. (1992) (19)
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. (2001) (19)
Sunitinib and bevacizumab in advanced solid tumors: A phase I trial (2008) (19)
The Bcl-2 transgene protects T cells from renal cell carcinoma-mediated apoptosis. (2003) (19)
A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (19)
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? (2008) (19)
Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. (2006) (18)
Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma (2006) (18)
Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma (2012) (18)
SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL (2008) (18)
Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy (2008) (18)
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors (2007) (18)
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma (2001) (17)
T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. (2006) (17)
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. (2006) (17)
Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study. (1982) (17)
Cost-utility assessment of amifostine as first-line therapy for ovarian cancer (1998) (17)
T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor (1994) (17)
TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction. (2007) (17)
Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study. (1982) (17)
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects. (1994) (17)
Inhibition of NFκB Induces Caspase-Independent Cell Death in Human T Lymphocytes (2001) (16)
Cytoprotection in the treatment of pediatric cancer: review of current strategies in adults and their application to children. (1999) (16)
Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC) (2004) (16)
Right renal mass with vena caval thrombus. (1990) (16)
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. (1999) (16)
Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma. (1990) (16)
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms. (2006) (15)
RANK Ligand: Effects of Inhibition (2010) (15)
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma (2008) (15)
Immunomodulatory Effects of Recombinant Interleukin‐3 Treatment on Human Alveolar Macrophages and Monocytes (1993) (15)
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. (1999) (15)
Phase 1 Trial of Subcutaneous IL-6 in Patients With Refractory Cancer: Clinical and Biologic Effects (2000) (15)
Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha. (1998) (15)
4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors (2007) (14)
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells. (1998) (14)
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma (2012) (14)
Nonspecific lymphocyte cytotoxicity in patients with malignant melanoma, renal cell carcinoma, and sarcomas, and in nontumor patients (1976) (14)
Expression of blood group antigen A by stage I non-small cell lung carcinomas. (1995) (14)
A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. (2006) (14)
In vivo Recombinant Adenovirus-mediated p53 Gene Therapy in a Syngeneic Rat Model for Colorectal Cancer (2004) (13)
Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. (2007) (13)
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab (2010) (13)
Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases (2007) (13)
Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study. (1983) (13)
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study. (1987) (12)
Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells (2005) (12)
Interleukin‐2: Use in solid tumors (1993) (12)
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. (1996) (12)
Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). (2004) (12)
Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma (2012) (12)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts) (2007) (12)
Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease (2008) (11)
Phase I trial of natural human interferon beta in metastatic malignancy. (1991) (11)
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer (1993) (11)
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. (2008) (11)
Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma (1993) (11)
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis. (2003) (11)
Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (2004) (11)
Downregulation of JAK 3 Protein Levels in T Lymphocytes by Prostaglandin E 2 and Other Cyclic Adenosine Monophosphate-Elevating Agents : Impact on Interleukin-2 Receptor Signaling Pathway (1999) (11)
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide. (1999) (11)
A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma (2002) (11)
Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma (2006) (10)
Inhibition of NFkappaB induces caspase-independent cell death in human T lymphocytes. (2001) (10)
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach (2010) (10)
Genitourinary Oncology: Current Status and Future Challenges (2011) (10)
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings. (1996) (10)
Treatment of severe aplastic anemia with antithymocyte globulin. (1982) (10)
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer (2004) (10)
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies (2003) (10)
Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: Lessons from a large phase III trial. (2004) (10)
964 CLINICAL BENEFIT OF SORAFENIB IN THE ELDERLY WITH ADVANCED RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF THE APPROACHES IN RENAL CANCER GLOBAL EVALUATION TRIAL (TARGETS) (2007) (10)
Pleiotropic effects of cytokines: clinical and preclinical studies. (1994) (10)
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. (2009) (10)
Renal cell carcinoma : immunotherapy and cellular biology (1993) (9)
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. (2003) (9)
Plasma exchange in the thrombotic microangiopathies (1985) (9)
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha. (1998) (9)
Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study. (1982) (9)
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor (2004) (9)
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors (2012) (9)
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma (2011) (9)
Phase-I trial of Ultrapure™ human leukocyte interferon in human malignancy (2004) (9)
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. (2002) (9)
5-Fluorouracil and Folinic Acid: a Phase I–II trial in gastrointestinal malignancy (2004) (9)
Chemotherapy trials in malignant pheochromocytoma: Report of two patients and review of the literature (1984) (9)
Interferon-g and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma (1999) (9)
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma (2004) (9)
Targeted Therapy for Renal Cell Carcinoma: A New Therapeutic Paradigm (2006) (8)
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer (1998) (8)
Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib (2008) (8)
IMMUNOTHERAPY OF HUMAN NEOPLASMS WITH TRANSFER FACTOR (1976) (8)
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. (2007) (8)
Role of everolimus in the treatment of renal cell carcinoma (2009) (8)
Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study. (2006) (8)
Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. (1983) (8)
4505 ORAL A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC) (2007) (7)
Neo-adjuvant intra-arterial chemotherapy in locally advanced bladder cancer. (1990) (7)
Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes. (2001) (7)
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer (2000) (7)
246 OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) (2009) (7)
Chemotherapy trials in malignant pheochromocytoma: report of two patients and review of the literature. (1985) (7)
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies. (1991) (7)
Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study. (1983) (7)
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells (1998) (7)
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin. (1977) (7)
Interactions Between Chemokines and Other Cytokines in Host Response to Tumor (1999) (6)
1098 Phase III study of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy (2003) (6)
Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells. (1998) (6)
Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study. (1987) (6)
Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy (2007) (6)
Amifostine: potential for clinically useful cytoprotection (1994) (6)
Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia. (2006) (6)
VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms (2004) (6)
Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients (2004) (6)
Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer (2009) (6)
GM 1 and Tumor Necrosis Factor-A , Overexpressed in Renal Cell Carcinoma , Synergize to Induce T-Cell Apoptosis (2008) (6)
Preliminary results of fast neutron treatments in carcinoma of the pancreas (1980) (6)
P-676 Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer (2003) (6)
A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor (2007) (6)
Management of advanced and extragonadal germ-cell tumors. (1993) (6)
Case report. Aplastic anemia. Effect of antithymocyte globulin on erythroid colony formation. (1978) (6)
A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC) (2007) (6)
Pegylated interferon alfa-2b as treatment of solid tumors (2003) (5)
Biologic therapy in patients receiving salvage treatment. (1994) (5)
Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy (2008) (5)
Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. (1996) (5)
Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches (2008) (5)
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study (1990) (5)
Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials (2011) (5)
860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2007) (5)
Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments (2008) (5)
Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC). (2006) (5)
Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis (2004) (5)
A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (2008) (5)
Cancer in the Spine (2006) (5)
Novel drugs for renal cell carcinoma. (2008) (5)
Renal masses simulating primary renal cell carcinoma in patients with advanced malignancies. (1994) (5)
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry (2004) (5)
What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma? (2008) (5)
Acute colonic pseudo-obstruction associated with interleukin-2 therapy. (1991) (5)
SORAFENIB THERAPY IN THE MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA WITH BRAIN METASTASES: RESULTS FROM THE ARCCS EXPANDED ACCESS PROGRAM (2008) (5)
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma (2004) (5)
Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results. (1982) (5)
Novel antineoplastic agents (2000) (5)
Frequency and survival impact of osseous metastases in patients with untreated renal cell carcinoma. (2004) (4)
Targeted Therapies: Bevacizumab and interferon-α in metastatic renal-cell carcinoma (2009) (4)
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
Biology of Renal Cell Carcinoma (1995) (4)
Burden of metastatic bone disease from genitourinary malignancies (2010) (4)
WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib (2007) (4)
Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers (2007) (4)
Novel drugs for renal cell carcinoma (2008) (4)
Clinical Management of Renal Tumors (2008) (4)
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study (1982) (4)
Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) (2008) (4)
Immunologic changes in renal cell carcinoma patients receiving gamma interferon. (1991) (4)
Tumor Infiltrating Lymphocytes in Human Renal Cell Carcinoma: Adoptive Immunotherapy and Characterization of Interleukin-2 Expanded Tumor-Infiltrating Lymphocytes (1991) (4)
Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study. (1980) (4)
SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL (2008) (4)
457 Interim evaluation of a multi-institution phase I/II study of antisense oligonucleotide GTI-2040 (G) and capecitabine (C) in patients with metastatic renal cell carcinoma (mRCC) (2004) (3)
Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus (2008) (3)
Neoadjuvant M-VAC with Intra-Arterial (I.A.) Cis-Platin in Locally Advanced Transitional Cell Carcinoma of the Bladder: Phase I/II Trial (1987) (3)
Phase II study of chlorozotocin in islet cell carcinoma (1983) (3)
The T Cell Death Knell (2001) (3)
7130 Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III target study (2009) (3)
Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment. (2006) (3)
Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (Pts) (2008) (3)
CD4+ T-Cell-Mediated Immunity to Cancer (2004) (3)
High-dose chlorozotocin in lung cancer: a Southwest Oncology Group Phase II Study. (1983) (3)
Uncommon Tumors of the Kidney (2012) (3)
Phase II evaluation of sequential hepatic artery infusion of 5‐fluorouracil and hepatic irradiation in metastatic colorectal carcinoma (1988) (3)
Enhancement in Specific CD 8 T Cell Recognition of EphA 2 Tumors In Vitro and In Vivo after Treatment with Ligand Agonists 1 (2008) (3)
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. (2009) (3)
Pegylated interferon alfa-2b as treatment of patients with solid tumors. (2003) (3)
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusions. (1994) (3)
Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference (2004) (3)
Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma (2004) (3)
Cutaneous Side Effects of Multikinase Inhibitors Used in Renal Cell Cancer (2007) (3)
Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients. (2006) (3)
Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview (2009) (3)
Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study. (2009) (3)
A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors (2004) (3)
856 SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) AND PRIOR CYTOKINE THERAPY: SUBGROUP ANALYSIS OF TARGETS (2007) (3)
858 SAFETY ANALYSIS OF THE ADVANCED RENAL CELL CARCINOMA SORAFENIB (ARCCS) STUDY, AN EXPANDED ACCESS PROGRAM (2007) (3)
Randomized trial of bevacizumab in advanced renal cell carcinoma (2008) (2)
Renal cell carcinoma: a new era? (2005) (2)
Interleukin-2 in Metastatic Renal Cell Carcinoma (2000) (2)
4517 POSTER Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) (2007) (2)
Epidermal growth factor receptor expression in renal cell carcinoma: Rationale for therapy with sidling blockade (2005) (2)
Renal cell carcinoma: a model system for novel drug development? (2008) (2)
Sunitinib in advanced renal cell carcinoma: New treatment option (2007) (2)
Phase IA/IB Trial of rhIL-6 in Patients with Refractory Malignancies: An Immunomodulatory Cytokine (1993) (2)
Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma (2011) (2)
Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors. (2007) (2)
Stable disease in renal cell carcinoma after using signal transduction inhibitors. (2010) (2)
Phase 1 trial of oral MAC-321 in subjects with advanced malignant solid tumors. (2004) (2)
Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis (2015) (2)
New antiangiogenic agents for renal cell carcinoma: Bevacizumab (2004) (2)
Overview of Childhood Pancreatic Tumors (1982) (2)
Chemoimmunotherapy of metastatic renal cell carcinoma. (1999) (2)
Phase II Trial of Sequential Chemotherapy and Low‐Dose Radiotherapy in Advanced Gastric Adenocarcinoma A Southwest Oncology Group Pilot Study (1987) (2)
Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-hodgkin's lymphomas (1995) (2)
Biomarkers in Renal Cell Carcinoma: What Next? (2011) (2)
Combination chemotherapy including VP-16 in poor prognosis germinal cell neoplasms (1982) (2)
Clinical status of the new cytoprotective agent, amifostine. (1994) (2)
Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction (2015) (2)
Adjuvant Therapy of Renal Cell Carcinoma (2008) (2)
Emerging drugs for renal cell carcinoma (2005) (2)
Raynaud's Phenomenon After Bleomycin Treatment (1978) (2)
Chlorozotocin: results in colorectal carcinoma treated with high and low doses (2004) (1)
Functional Assessment of Cancer Therapy--Kidney Symptom Index (2015) (1)
Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma (2002) (1)
Abstract A36: Plasma biomarkers predicting outcome in patients with advanced RCC: Results from the sorafenib phase III TARGET trial (2009) (1)
New antiangiogenic agents for renal cell carcinoma: Interferon alfa and thalidomide (2004) (1)
T Cells Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of Gangliosides Expressed by the Renal Cell Carcinoma Cell (2003) (1)
Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. (2006) (1)
Renal Cell Carcinoma: Background (2008) (1)
Pazopanib: An Overview of its Development as a Therapy for Patients with Metastatic Renal Cell Carcinoma (2011) (1)
Sunitinib ReversesType-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (1)
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer (2004) (1)
Current approaches in cytoprotection: the role of amifostine (Ethyol) in altering and ameliorating toxicities in cancer therapy. (1996) (1)
Carcinomas Gangliosides Expressed on Renal Cell B in T Cells by κ Degradation of NF-Finke (2004) (1)
213 von Hippel-Lindau (VHL) and p53 dependent cytotoxic effects of the proteasome inhibitor bortezomib (PS) in human renal cancer cells (2004) (1)
Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms. (1988) (1)
SUNITINIB MALATE (SU11248) – EFFICACY IN RENAL CELL CARCINOMA (RCC) (2006) (1)
In vivo regulation of macrophages in cynomolgus monkey endometrium: during menstrual cycle and after treatment with antiprogestin or GNRH-A (1995) (1)
Intravenous MST-997 (TL- 909) formulated in intralipid 20% administered weekly in subjects with advanced malignant solid tumors: A phase I dose-escalation study (2005) (1)
65 POSTER Safety of Volociximab as a monotherapy and in combination with chemotherapy the result of three phase II studies (2006) (1)
Phase I trial of vinblastine plus phenytoin Pharmacokinetic analysis (1996) (1)
Plasma exchange was more effective than plasma infusion for thrombotic thrombocytopenic purpura (1991) (1)
Potential Clinical Applications in Cancer Therapy (1994) (1)
A phase I trial of intrapleural recombinant human interferon α (rHuIFNα2b) in patients with malignant pleural effusions (2005) (1)
Clinical trials in colorectal cancer: Experience of the Gastrointestinal Tumor Study Group and the Southwest Oncology Group (1987) (1)
IMMUNOTHERAPY OF STAGE II MALIGNANT MELANOMA AND RENAL CELL CARCINOMA WITH TRANSFER FACTOR: CLINICAL RESULTS1 (1979) (1)
High dose AZQ in renal cancer (1986) (1)
Cancer Immunotherapy at the Crossroads (2004) (1)
Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. (2006) (1)
Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features (2008) (1)
Phase IV evaluation of clinical outcomes of PROCRIT in anemic cancer patients receiving chemotherapy (1994) (1)
Clinical Management of Renal Cell Cancer (1990) (1)
Mitoguazone in advanced renal carcinoma: a phase II trial of the Southwest Oncology Group. (1983) (1)
Zometa® (Zoledronic acid) reduces skeletal complications in patients with bone metastases from renal cell carcinomain patients with bone metastases from renal cell carcinoma (2003) (1)
Impaired Signal Transduction in Tumor Infiltrating T Cells from Patients with Renal Cell Carcinoma (1995) (1)
Therapeutic Use of Recombinant Proteins (1999) (1)
Receptor-Independent Pathways Apoptosis through Receptor-Dependent and Renal Cell Carcinoma Tumors Induce T Cell (2008) (1)
Prolonged survival of a patient with Richter's syndrome. Report of a 10-year follow-up. (1981) (1)
Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. (2008) (1)
How I treat renal cell carcinoma. (2008) (1)
Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. (2011) (1)
CarcinomasExpressed on Renal Cell B in T Cells by κ Degradation of NF (2013) (0)
Medical Management of Metastatic Renal Cell Carcinoma (2015) (0)
Book Review: Diagnostic and Therapeutic Antibodies (2000) (0)
Acknowledgement to the Reviewers (2017) (0)
634: 4-Hydroxyneonal is Expressed on Renal Cell Carcinoma and it Promotes Apoptosis of T Lymphocytes (2005) (0)
Phase II trial of Fluorouracil, Leucovorin and Interferon-α (1994) (0)
A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors. (2004) (0)
Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience (1991) (0)
Alterations in NF k B Activation in T Lymphocytes of Patients With Renal Cell Carcinoma (1999) (0)
Clinical Results and Characterization of Tumor-infiltrating Lymphocytes with or without Recombinant Interleukin 2 in Human Metastatic Renal Cell Carcinoma 1 (2006) (0)
The Cost of Hope: a candid roundtable discussion. (2013) (0)
The Role of Gangliosides in Renal Cell Carcinoma (2009) (0)
Durable complete responses and near complete responses to sunitinib in metastatic renal cell carcinoma (2007) (0)
Chemotherapy for Metastatic Parathyroid Carcinoma-Reply (1984) (0)
VHL gene mutation and hypermethylation in patients with renal cell carcinoma: Preliminary results and clinical correlation (2005) (0)
Effects of interleukin-12 on interferon-gamma production by peripheral blood and tumor infiltrating T-lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion (1996) (0)
INHIBITION OF NF kappa B BINDING IN T CELLS OF PATIENTS WITH RENAL CELL CARCINOMA (RCC): THE ROLE OF IMMUNOSUPPRESSIVE GANGLIOSIDES (1999) (0)
Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA (2008) (0)
631: TNFα and Gangliosides Work Synergistically to Induce Apoptosis of T Lymphocytes in Renal Cell Carcinoma (2005) (0)
Bladder Cancer and Current Evidence for Treatment December (2017) (0)
Dilemmas in the Management of Treatment-Naïve Patients With Metastatic Renal Cell Carcinoma (2010) (0)
Carcinoma of the Unknown Primary (2006) (0)
Functional Imaging of Renal Cell Carcinoma (2008) (0)
Renal Cell Carcinoma Metastatic to the Pancreas: Clinical and Therapeutic Aspects (2008) (0)
Clinical Cancer esearch ing , Diagnosis , Prognosis markers Predicting Outcome in Patients with Advanced al Cell Carcinoma : Results from Sorafenib Phase III atment Approaches in Renal Cancer R bal Evaluation (2010) (0)
Signal Transduction Inhibitors in Renal Cell Carcinoma (2008) (0)
Targeted Therapies for Renal Cell Carcinoma (2011) (0)
Nonsurgical Management of Metastatic Renal Cell Carcinoma (2008) (0)
Book Review: Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What can be Done. (2004) (0)
Randomized trial of MAID chemotherapy with G-CSF alone or with G-CSF plus varying doses of interleukin-6 (1996) (0)
Targeted therapy for renal cell carcinoma (2011) (0)
Necessary for IL-12-Mediated Regression of the The CXC Chemokines IP-10 and Mig Are (2013) (0)
Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme (2005) (0)
Subject Index Vol. 78, 2010 (2010) (0)
Suppression of tcr-cd3 linked tyrosine phosphorylation of normal peripheral blood T cells by tumor supernatants from renal cell carcinoma (RCC) (1996) (0)
Retroperitoneal Extragonadal Germ Cell Tumors Associated with Unrecognized Testicular Cancer (1987) (0)
in the Treatment of Thrombotic (2016) (0)
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community. (2006) (0)
Hematologic effects of recombinant human Interleukin-6 (rhIL-6) in sarcoma patients receiving maid chemotherapy: phase I trial (1994) (0)
1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC) (2011) (0)
APhase I Pharmacokinetic and Pharmacodynamic Study of S-3304 , a Novel Matrix Metalloproteinase Inhibitor , in Patients with Advanced and Refractory SolidTumors (2007) (0)
Thanks to Reviewers2003 (2003) (0)
Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer (2020) (0)
Translating Biology to Clinical Practice: Evolving Strategies for the Treatment of Renal Cell Carcinoma (2008) (0)
GM2 overexpression in renal cell carcinoma: potential role in tumor induced immune dysfunction (2005) (0)
APhase I Study with Neratinib ( HKI-272 ) , an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor , in Patients with Solid Tumors (2009) (0)
Phase I and Pharmacology Studies (2004) (0)
The 43rd Annual Meeting of the American Society of Clinical Oncology (2007) (0)
Expression of caveolin-1 in renal neoplasms. (2006) (0)
Thanks to Reviewers2002 (2002) (0)
Sorafenib in Renal Cell Carcinoma (2009) (0)
The role of sunitinib in metastatic renal cell carcinoma (2008) (0)
The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC) (2008) (0)
Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma (2012) (0)
Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study. (2004) (0)
Combination chemotherapy for metastatic carcinoma of the ampulla of Vater—report of three cases (1984) (0)
P57 Elderly patients with advanced renal cell carcinoma (RCC): combined experience with sorafenib from the randomized phase III TARGET and the European (EU) and North American (NA) Open-Access (ARCCS) trials (2009) (0)
ACTIVATION INDUCED CELL DEATH (AICD) IN T LYMPHOCYTES FROM PATIENTS WITH RENAL CELL CARCINOMA (RCC): A POTENTIAL MECHANISM OF TUMOR IMMUNE ESCAPE (1999) (0)
RAD-001: future directions (2009) (0)
Prostaglandin e2 (pge2) modulates the expression of jak3 in naive and activated t lymphocytes (1996) (0)
Renal Cell Carcinoma: Development of a New Treatment Paradigm (2006) (0)
Diagnostic and Management Issues in Gallbladder Carcinoma (2017) (0)
2008 Best of the Rest in Urological Survey (2008) (0)
IL-2 Based Combination Therapy of Malignant Disease: Summary of the Phase I Experience at the Cleveland Clinic (1992) (0)
Acknowledgement of Reviewers (2004) (0)
Acknowledgement to the Reviewers (2017) (0)
493 POSTER Down regulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest (2006) (0)
Biochemical modulation of fluorouracil in patients with metastatic colorectal cancer (2001) (0)
Cytokine Therapy of Metastatic Renal Cell Carcinoma: The Cleveland Clinic Experience (1995) (0)
Intra-ovarian action of progesterone in monkeys: characterization of ovarian progesterone receptor distribution. (1996) (0)
Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma. (2009) (0)
Renal Cell Carcinomas Promotes T Cell Induction of GM 2 Expression on α TNF-and (2007) (0)
Phosphorylation of tyrosine 656 in topoisomerase IIβ is required for enzymatic activity and anti-tumor drug sensitivity (2007) (0)
Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy (2010) (0)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma? (2010) (0)
Combined-modality Treatment of Renal Cell Carcinoma (2000) (0)
Acknowledgment to Referees (2014) (0)
Poor Risk Renal Cell Carcinoma Patients: Role of New Agents (2007) (0)
Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis (2004) (0)
Comprar Renal Cell Carcinoma | Ronald M. Bukowski | 9781588297372 | Humana Press (2009) (0)
Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL (2007) (0)
Phase I Clinical Trial of Interleukin 2 and a-Interferon: Toxicity and Immunologie Effects1 (2006) (0)
Cell Carcinoma? Can We Predict Long-Term Survival After Pulmonary Metastasectomy for Renal (2013) (0)
Suppressor Cells in Oncology (2018) (0)
Original article Phase II trial of capecitabine and rHu-interferon--2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity (2007) (0)
Contents Vol. 78, 2010 (2010) (0)
233 A phase IV study of epoetin alfa examining clinical outcomes in anaemic cancer patients receiving chemotherapy (1995) (0)
203 Modulation of DNA damage induced apoptosis by the proteasome inhibitor bortezomib (PS) in human colorectal and non-small cell lung cancer cells is p53-dependent and NK-kB-independent (2004) (0)
Activation of human peripheral blood immune cells in vitro by sodium stibogluconate (SSG) and SSG/IL-2 combination. (2006) (0)
Caspase-1 and-3 Apoptosis Without Detectable Activation of Lymphocytes Induces Caspase-Dependent B Activity in Human T κ Inhibition of NF (1999) (0)
Optimizing utilization of targeted therapies in genitourinary cancers. (2008) (0)
Meet Our Editorial Board Member (2018) (0)
Strategies for selective modulation of Vinca alkaloid cytotoxicity by the anti-epileptic phenytoin: experimental and clinical experience (1994) (0)
Book Review: Suicide Gene Therapy: Methods and Reviews. (2004) (0)
Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma? (2007) (0)
Development of novel signal transduction inhibitors: Recent phase I trials (2002) (0)
Efficacy and safety of sorafenib in patients with advanced clear-cell renal cell carcinoma (RCC) with diabetes: Results from the phase III TARGET study. (2009) (0)
Abstract 1626: Tyrosine phosphorylation of RIN1 modulates the anti-proliferative effects of sorafenib and sunitinib in renal cell carcinoma (RCC) (2010) (0)
Phase I study of interleukin-4 (rHuIL-4) combined with chemotherapy in gastrointestinal (GI) malignancies (1997) (0)
Pegylated I nterferon A lfa-2b T reatment f or P atients W ith Solid T umors: A P hase I /II S tudy (2002) (0)
Nigro regimen treatment of squamous cell cancer of the anus (2007) (0)
Immunologic studies of peripheral blood lymphocytes and lymph nodes in Hodgkin's disease. A preliminary report. (1985) (0)
Sorafenib treatment of clear-cell renal cell carcinoma (CCRCC) and colorectal carcinoma (CRC) cells: Differential effects on gene expression and cell death pathways (2007) (0)
Renal cell carcinoma: immunotherapy revisited (2011) (0)
Defining Clinical Endpoints in Renal Cell Carcinoma (2006) (0)
Imag Bio Ren Tre Glo Carol Abst (2010) (0)
Immunologic studies of alveolar macrophages from patients with metastatic renal cell carcinoma. (1990) (0)
An oral fluoropyrimidine prodrug with activity in colorectal cancer (2001) (0)
48 POSTER Distinct gene expression profiles and cell death pathways in clear-cell renal cell carcinoma (CCRCC) and colorectal carcinoma (CRC) cells:r elationship to hypoxia, von Hippel Lindau protein (pVHL) expression and anti-tumor activity of sorafenib (2006) (0)
Bladder Cancer and Current Evidence for Treatment (2007) (0)
Referee acknowledgement for 2019 (2020) (0)
Specific chemokine expression in vivo correlates with highly selective leukocytic infiltration (1994) (0)
Suppression of nficb activation in normal T cells by soluble products from renal cell carcinoma explants (1996) (0)
S9 Renal Cell Carcinoma : Developing Therapeutic Approaches(Keynote Lecture,Symposium 9「Recent Trend of Treatment for Metastatic Renal Cell Carcinoma」) (2006) (0)
GM2 Expression in Renal Cell Carcinoma Cells and T Lymphocytes: Potential Role in Tumor-Induced Immune Dysfunction (2005) (0)
Book Review: Renal Cell Carcinoma (2000) (0)
Development of a new treatment paradigm has stimulated the interest of investigators and clinicians in renal cell carcinoma (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronald M. Bukowski?

Ronald M. Bukowski is affiliated with the following schools: